PMC10465174_01
Timeline of cardiac enzyme changes. In this figure, we charted the changes in cardiac enzyme levels during the treatment from the day of the patient's first chemotherapy as the starting point for calculation.
fimmu-14-1243980-g001.jpg
PMC10465174_01_fimmu-14-1243980-g001.jpg
f1
Before the second cycle of treatment, all the cardiac enzymes returned to normal on recheck ( Figure 1 ).
Changes in target lesion size during treatment. (A) CT scan with chest contrast (before immunotherapy). (B) CT scan with chest contrast (after 4 months of sugemalimab treatment). The red arrows in the figure mark the target lesions of enlarged lymph nodes. Chest imaging showed a reduction in the size of the hilar lymph nodes from 2.3 cm to 1.4 cm after four cycles of treatment, with an assessment of PR at the end of treatment.
fimmu-14-1243980-g002.jpg
PMC10465174_01_fimmu-14-1243980-g002.jpg
f2
Review of CT scan with contrast for evaluation of the target lesion prompted the efficacy of the final treatment as PR ( Figure 2 ).